



ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product

February 26, 2014 06:00 AM Eastern Standard Time

SAN ANTONIO--([BUSINESS WIRE](#))--ViroXis Corporation is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of an over-the-counter (OTC) sandalwood oil-containing product. The long-term agreement includes a licensing fee, milestone payments and royalties based on product sales. The pharmaceutical partner is exclusively dedicated to dermatology and is a world leader in dermatology products with an extensive product portfolio available in 80 countries. The license agreement anticipates worldwide commercialization of the OTC product, with an initial product launch in the U.S. anticipated in early 2015.

“ViroXis has quickly emerged as a leader in the development of botanical drug products”

ViroXis has completed an open label Phase 2 study to support the launch of its OTC product, and a publication describing the study is in preparation. A second OTC product is in development.

“ViroXis has quickly emerged as a leader in the development of botanical drug products,” said Ian Clements, Chief Executive Officer of ViroXis Corporation. “The strong clinical and scientific focus of our botanical programs has created interest among strategic partners, as demonstrated by this global licensing deal we’ve signed for our first OTC product.”

About ViroXis

ViroXis' mission is to develop and commercialize novel, safe and effective prescription and over-the-counter botanical products for the treatment of viral skin conditions. Botanically-derived drugs have formed the backbone of the pharmaceutical industry and the 2004 FDA botanical drug development guidelines allow for streamlined development of drugs that are mixtures of plant-derived compounds and that have a historical record of safe human use. ViroXis' botanical drug development program utilizes sandalwood oil sourced exclusively from TFS Corporation, Ltd. of Australia (ASX: TFC), the world's largest cultivator of sustainably grown East Indian sandalwood trees.

About TFS

TFS Corporation Ltd (ASX: TFC) is an owner and manager of the world's largest East Indian sandalwood plantations. TFS' first planting in northern Australia was in 1999 and it now manages approximately 7,600 hectares on behalf of both retail and institutional investors. TFS is committed to adopting and maintaining the highest environmental and ethical standards in all

aspects of its business and is ranked as an industry leader in ethical and sustainable practices by Oekom Research, a leading international ratings agency. In 2009, TFS entered the prestigious Forbes Asia Pacific's 'Best Under a Billion', which recognizes the Top 200 companies from more than 25,326 publicly-listed firms in the Asia/Pacific region with revenue of less than \$1 billion.

Contacts

ViroXis Corporation
Mr. Ian Clements, CEO, 210-399-2315
ian@viroxis.com

